JLE

European Journal of Dermatology

MENU

Drug-induced bullous lichenoid eruption: a side effect of nivolumab triggered by the TLR agonist imiquimod Volume 31, issue 1, January-February 2021

Figures


  • Figure 1
Authors
1 Dermatology Department, CHU Bordeaux, 1 av. Jean Burguet F-33000 Bordeaux, France
2 Pathological Department, CHU Bordeaux, Avenue du Haut Leveque, F-33600 Pessac, France
3 INSERM U-1035, Univ. Bordeaux, F-33000 Bordeaux, France
4 INSERM U-1053, Bordeaux Research in Translational Oncology team 3 Oncogenesis of cutaneous lymphomas, Univ. Bordeaux, F-33076 Bordeaux, France

Advances in our understanding of the network between tumour cells and their microenvironment has led to the emergence of novel combined strategies to avoid tumour immune escape in metastatic melanoma. Toll-like receptor (TLR) agonists are immunomodulators that stimulate innate immunity. Previous reports have suggested that imiquimod could be a useful and safe treatment for melanoma. We report a case of a patient treated with anti-PD1 associated with topical imiquimod who developed an acute and severe [...]